Search results
Showing 841 to 855 of 2548 results for methods
Awaiting development Reference number: GID-QS10035 Expected publication date: TBC
Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
In development Reference number: GID-TA10832 Expected publication date: TBC
In development Reference number: GID-TA11023 Expected publication date: TBC
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.
Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446
In development Reference number: GID-TA11552 Expected publication date: 25 September 2026
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
View recommendations for TA160Show all sections
Type 2 diabetes prevention: population and community-level interventions (PH35)
This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.
This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.
IDKmonitor and Promonitor) is recommended, specifically on:- the best methods to measure tumour necrosis factor (TNF)-alpha-inhibitor...
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.